Cancer and cardiovascular disease are two leading causes of mortality worldwide, and cancer survivors have an increased cardiovascular risk due to shared risk factors with cardiovascular disease and the potential for cardiotoxicity related to cancer therapies, now referred to as cancer therapy-related cardiovascular dysfunction (CTRCD) [1]. CTRCD is a main cause of chemotherapy discontinuation, morbidity, and mortality in this patient population [2].
